FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:934-936 October 5, 1995 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Chemotherapy and radiotherapy of Hodgkin's disease are among the major advances in clinical oncology, but these successes have not been matched by progress in identifying the target cell. Further improvements in the treatment of Hodgkin's disease, perhaps involving biologic manipulation, could result from a better definition of the cell of origin.¹ One reason that the diagnostic cell of Hodgkin's disease, the Reed–Sternberg cell, remains enigmatic is the heterogeneity of Hodgkin's disease, which is evident histologically and by immunophenotypic analysis.² Reed–Sternberg cells have been variously identified as B or T lymphocytes, lymphocytes of uncommitted lineage, monocytes, dendritic cells, and even as . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.